TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor to treat ovarian or breast cancers; and TSR-011, an anaplastic lymphoma kinase inhibitor, which is in phase 1/2a dose escalation clinical trial in cancer patients. The company also offers KEYTRUDA and OPDIVO, an anti-PD-1 antibody products, for the treatment of certain non-small cell lung cancers; and develops immunotherapy antibody product candidates targeting PD-1 (TSR-042) and TIM-3 (TSR-022), as well as LAG-3 and bi-specific antibody product candidates targeting PD-1/TIM-3, PD-1/LAG-3, and an additional bi-specific combination to treat various tumors. It has strategic research collaboration with Myriad Genetics, Inc. TESARO, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Tesaro's ovarian cancer drug study succeeds, shares soar June 29 (Reuters) - Tesaro Inc said its experimental ovarian cancer drug niraparib met the main goal of prolonging survival in patients, without the disease worsening, in a late-stage trial, sending its shares to a record high. The Waltham, Massachusetts-based company's shares more than doubled to $77. About 22,000 women are diagnosed with ovarian cancer in the United States every year, and nearly 80 percent are diagnosed after it has progressed to a severe stage.
What a squeeze coming! All the remaining shorts who averaged up their attacks are now forced to cover. Big days coming congrats longs!
Analysts hike outlook for Waltham’s Tesaro after ovarian cancer drug data http://www.bizjournals.com/boston/b...ook-for-waltham-s-tesaro-after.html?ana=yahoo
Analyst Upgrade/Downgrade Update Brokerage firm: Lake Street Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Buy Previous Price Target: $114 Current Price Target: $150
$TSRO jumps 5.4% to 165.11 in PreM trading after its Niraparib treatment for Ovarian Cancer was approved by the U.S. FDA; No Position
+5% pre market on news: Tesaro Secures FDA Nod for Ovarian Cancer Drug Tesaro Inc. (TSRO) has announced that it has secured an early approval from the U.S. Food And Drug Administration (FDA) for its key drug Zejula (niraparib) for treatment of recurrent ovarian cancer.
